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ABSTRACT 
There are unique challenges facing the diagnosis and management of tuberculosis infection in 
children. Following exposure to an infectious tuberculosis case and subsequent infection, 
children frequently progress to tuberculosis disease more rapidly than adults. Increasingly, 
investigators recognize the concept of sub-clinical disease, an entity referring to early 
asymptomatic disease. Our understanding of the pathogenesis of tuberculosis in children 
remains limited but could be improved through animal models, laboratory studies evaluating 
the responses of blood or respiratory samples to mycobacteria in vitro, as well as evaluating 
immune responses in children exposed to tuberculosis. Identifying children with sub-clinical 
disease, at high risk of progression to clinically apparent disease, through biomarker discover, 
would mean that treatment could be targeted to those most likely to benefit. These studies 
could be embedded in large observational or interventional cohorts. The optimization and 
discovery of novel treatments for tuberculosis infection in children need to account for 
mechanisms of action of tuberculosis drugs as well as child-specific factors including 
pharmacokinetics and appropriate formulations. In this article we present the result of 
discussions at a large international meeting and the series of research priorities that were 
developed. 
 
 
 
  
  
BACKGROUND 
Current Situation 
The conventional conceptual framework when considering the pathogenesis of tuberculosis in 
children is linear and unidirectional, with two distinct dichotomous clinical states: tuberculosis 
infection and tuberculosis disease. Children are exposed to Mycobacterium tuberculosis via 
aerosolized droplets. Some develop tuberculosis infection, defined as immunological evidence 
of sensitization to M. tuberculosis, and from this state, some progress to tuberculosis disease, 
defined as the presence of symptoms and signs of tuberculosis, usually together with 
radiological, and sometimes microbiological, evidence of disease. Young children are at 
particularly high risk of progressing from infection to disease and are also more likely than 
adults to develop severe, debilitating forms, such as tuberculous meningitis.1 Worldwide nearly 
seventy million children currently have tuberculosis infection,2 and each year about one million 
children progress to tuberculosis disease.3 A quarter of them die, representing one of the top ten 
causes of under-five mortality.4  
Treating Tuberculosis Infection 
In order to prevent this mortality, it is increasingly recognized that it will be necessary to 
identify and treat children with tuberculosis infection in addition to children with tuberculosis 
disease.5 The World Health Organization, and almost every national tuberculosis guideline, has 
for many years, advocated the provision of isoniazid preventive therapy to young children, 
following exposure to an infectious case of tuberculosis.6 In spite of these recommendations, 
however, tuberculosis infection treatment is rarely implemented in high tuberculosis-burden 
settings.7  
Developing A Research Agenda 
Failures in implementation of preventive therapy can result from the perception that a large 
numbers of well children require treatment to prevent each case, and that treatment is long.8,9 It 
is hoped that in the future biomarkers will be discovered that can predict progression to 
tuberculosis disease. It is also anticipated that research will lead to improvements the 
management of tuberculosis infection in children. A better framework of feasible and achievable 
research in paediatric tuberculosis infection would provide direction to researchers and 
funders and allow for the rational development of a research agenda. On 27-28 September 
2017, 165 global participants attended a two-day workshop in Dubai with the aim of arriving at 
consensus on the priorities required to better understand, diagnose and treat tuberculosis 
infection. The meeting was supported by the Division of AIDS, National Institute of Allergy and 
  
Infectious Diseases and hosted at the Harvard Medical School Center for Global Health Delivery–
Dubai. A session focused on children, and presentations were given with subsequent discussion 
from all attending participants. Themes were then taken forward amongst several paediatric 
investigators after the meeting, and over the course of multiple conference calls and cycles of 
written feedback consensus was arrived at for research priorities that are described in this 
manuscript and in Table 1.  
 
PATHOPHYSIOLOGY 
Evolving Concepts in Childhood Tuberculosis 
An improved understanding of the natural history, pathophysiology and immune responses 
associated with paediatric tuberculosis would enhance our current ability to identify those 
children most likely to benefit from treatment of infection. It is increasingly clear that the 
concept of latent infection versus active disease is too simplistic, given the dynamic spectrum 
from exposure to disease, with children potentially moving in both directions (Figure 1).10,11 The 
concept of sub-clinical and incipient disease has gained prominence in recent years referring to 
early disease in asymptomatic persons, which is either evident radiologically (sub-clinical) or 
not (incipient).12,13 Although most investigation into these early clinical states has been in 
adults, this concept in not novel in children.14,15 Children progress more rapidly than adults 
from exposure to infection to clinically apparent disease, and hence represent a unique cohort 
in which to study the pathophysiology of sub-clinical disease and associated host responses. In 
the interest of clarity, we use the term sub-clinical to refer to both sub-clinical and incipient 
states for the remainder of this review.   
The distinction between sub-clinical and clinically apparent disease is likely to be due to a 
quantitative difference in bacterial load, rather than a change in the replication state of the 
mycobacteria.16 This has implications for novel diagnostics as the host immunological and 
metabolic responses may be measurable in sub-clinical disease and similar to those in clinically 
apparent disease. A current research priority is to identify children with sub-clinical disease 
who are thought to be at highest risk of developing clinically apparent disease in the future. As 
is discussed later, this has been undertaken in adolescent and adults but not in younger 
children.17 
Following exposure to M. tuberculosis, several outcomes are possible.18,19 Organisms can: 1) be 
cleared by immune responses, 2) progress to clinically apparent disease, or 3) reach an 
equilibrium in which the organism is not cleared, but is contained by the host in a dynamic state 
  
that may fluctuate over time. The pathogen may later be cleared, or it may overcome the host 
defenses and clinical symptoms and signs of disease develop (Figure 2). In high tuberculosis-
burden settings, the force of infection is so great that frequent re-infection is also common, 
following either clearance or containment of the organism.20 In the absence of large-scale 
longitudinal studies, including repeated sampling of the same individuals, it is therefore difficult 
to ascertain whether progression to disease occurs following failure of restriction of the initial 
infection, or results from a new exposure. Household contact studies of exposed children of all 
age groups, with longitudinal follow up and sampling provide a unique opportunity to define 
these phenotypes.21  
Research Directions 
Our current understanding of risk factors for progression to disease following exposure to M. 
tuberculosis in children is limited, with few studies exploring this from epidemiological, clinical 
or immunological perspectives.22 It is clear that host responses vary with age,23 and research to 
better understand the natural history of childhood tuberculosis, accounting for age and 
exposure, is urgently warranted. Laboratory assays utilizing blood from children of various age-
groups and stimulated with live mycobacteria or mycobacterial antigens in vitro could provide 
insight into pathways that are activated or suppressed.24,25 Animal studies could be utilized to a 
greater extent as few studies have investigated the impact of age on immune response in 
juvenile animal models. Mouse, guinea pig, rabbit and non-human primate models could all be 
explored. 
Much of the human interaction with M. tuberculosis occurs initially at a mucosal and then a 
lymphoid level. Although studies in adults have demonstrated differences in immune responses 
in lung, pericardial and mucosal tissue compared to blood, and have highlighted the crucial role 
of resident innate cells including alveolar macrophages, mucosal associated invariant T (MAIT) 
cells, Th17 cells and IL17-producing γδ T cells,26-36 these studies have not been conducted in 
children due to ethical and physical challenges of sample collection. Novel in vitro approaches, 
including human lung explant studies and alveolar macrophage cultures could be undertaken by 
paediatric researchers.27,37 An additional challenge is to determine the time of exposure. The 
child may have been recently exposed, exposed some time ago to the identified source case, or, 
in a high burden setting, exposed to other infectious cases in the past. Trying to make sense of 
the immunological response when the time since exposure is unclear can be challenging (Figure 
3). The best, and most efficient, way of exploring these responses would be to embed basic 
science studies within cohorts of children who are being recruited to other studies, such as 
epidemiological studies of household contacts or clinical trials, where the recruitment entry 
point is a defined exposure. Recent paediatric treatment trials such as SHINE, TB-CHAMP and 
  
SURE, as well as other observational cohorts, have already adopted this model, collecting 
samples for adjunctive biomarker assays.38,39 
 
DIAGNOSIS OF INFECTION    
Currently Available Tests 
The current tests of infection, the tuberculin skin test (TST) and interferon-gamma release assay 
(IGRA), evaluate whether a child mounts an acquired cellular immune response to M. 
tuberculosis.40,41 However, these tests do not indicate whether a persistent or progressive 
infection is present, or if the infection has been cleared.42,43 In addition, in children with 
confirmed tuberculosis disease up to 30% have negative tests,44 and the sensitivity of these 
tests is especially poor in young children living in high tuberculosis-burden settings.45 
Moreover, while children with a positive test result are twice as likely to develop disease as 
those with a negative test, the vast majority of children with a positive test do not develop 
disease.43 (Figure 4). Nonetheless, epidemiological and clinical data suggest that young children 
with TST and/or IGRA conversion have increased risk of disease progression, supporting use of 
these tests to inform decision-making around use of  tuberculosis infection treatment. Because 
the specificity of IGRAs is greater than TST in younger BCG-vaccinated children,46-49 research 
into decreasing the requisite blood volume for, and improving the technical test performance of, 
IGRA in young children, as well as developing a T cell diagnostic platform that could be used at 
the point-of-care for tuberculosis infection, with small quantities of blood, is warranted. 
Recent Developments 
In regions of the world where contact management and delivery of tuberculosis infection 
treatment is challenging due to the caseload of tuberculosis disease and limited resources, a test 
that could identify sub-clinical disease (Figure 1) would be useful to target tuberculosis 
infection treatment to those most likely to benefit from it. A recent study in South African 
infants demonstrated that conversion from negative to very high interferon-gamma levels 
(>4.00 IU/ml) in otherwise asymptomatic infants was associated with a 40 times risk of disease 
progression compared to non-converters.50 These results suggest that high IGRA values may be 
a marker of sub-clinical disease in infants. While not evaluated in young children, a recent study 
of 6,000 IGRA-positive South African adolescents has identified a 16-gene transcriptomic 
signature that defined a short-term risk of progression to tuberculosis disease.17 This signature 
is being taken forward in a clinical trial to validate decision-making around tuberculosis 
infection treatment in adults.51  
  
Future Directions 
The study of candidate biomarkers of sub-clinical disease has the potential to reduce morbidity 
and mortality from tuberculosis in young children. However, designing studies that could lead 
to tests able to discriminate between children who ultimately will develop disease and those 
that will not is challenging. As most children with tuberculosis infection will not progress to 
disease, studies need to be large. Also, the standard of care for young children (<5 years) and for 
children with immunosuppressive conditions is to provide tuberculosis infection treatment.6 
Therefore, it is ethically unacceptable to observe children without treatment in order to identify 
biomarkers. Recent guidance is to additionally consider treating older children with evidence of 
tuberculosis infection.52 One options would be to evaluate children contacts of drug-resistant 
tuberculosis, as most guidelines advocate close observation without treatment. The study of 
children treated for tuberculosis infection may also be informative, to determine if biomarker 
changes signify mycobacterial clearance, potentially of use in the evaluation of novel regimens 
or treatment shortening trials. Finally, translating the complex laboratory procedures necessary 
to measure immunological parameters or identify differentially expressed transcripts into 
affordable true point-of-care tests, for widespread use in low resource settings, will require 
collaboration between multiple disparate scientific and commercial partners. 
Efforts to date have mainly sought to validate diagnostic biomarkers in children that have been 
discovered in adults. However, accurate diagnostic biomarkers in adults may not translate well 
into diagnostic accuracy in children, as young children have differently regulated immune 
systems, have a pre-pubertal hormonal status, may more frequently suffer from malnutrition, 
have received BCG immunization and other childhood vaccinations more recently, and may lack 
the immunological memory conferred from lifetime exposures to microbial and other 
environmental antigens.18,19,53,54 Therefore, efforts should not only be directed at biomarker 
validation, but also at biomarker discovery in young children. Challenges around the timing of 
sampling in relation to exposure are similar as for the evaluation of the immune response 
(Figure 3) and there are significant transcriptomic changes with age, co-infections, nutritional 
status, recent vaccination and even time of day.55  
 
TREATMENT OF TUBERCULOSIS INFECTION 
Treatment Strategies 
Children with tuberculosis infection are clinically well, and most do not progress to tuberculosis 
disease. Therefore, unpalatable or intolerable medications would not be acceptable from a risk-
  
benefit perspective. This leaves only a handful of currently available drugs for tuberculosis 
infection treatment - the rifamycins, isoniazid, and the fluoroquinolones. When pharmacokinetic 
parameters and safety profiles are better understood in the youngest children, it may also 
include delamanid, bedaquiline and other novel drugs. The ideal tuberculosis infection 
treatment regimen would be safe, short, well-tolerated, effective, compatible with antiretroviral 
medications and affordable, while easy to implement for health services and families. If this 
ideal is not possible, then it may be appropriate to sacrifice some degree of efficacy for safety, 
duration, or tolerability. Multiple options, including easier administration (such as a cutaneous 
patch etc.) or a very long acting agent (only needed to be given once every week) would also be 
advantageous.  
The evidence base for current treatments of tuberculosis infection has largely been gained from 
large-scale clinical trials, employing effectively a ‘trial and error’ approach. A more mechanistic 
and considered strategy, however, may provide advantages. Several mechanisms can be 
employed to treat tuberculosis infection. These may include: 1) eliminating all mycobacteria; 2) 
killing enough of the mycobacteria, or weakening them sufficiently to allow the immune system 
to eliminate or contain them; 3) stimulating the mycobacteria out of their non-replicating state 
so that they can be eliminated by other drugs or the immune system; 4) 
stimulating/manipulating the immune system so it is better able to eliminate or contain the 
mycobacteria; or 5) some combination of the above. All current drugs used for the treatment of 
tuberculosis infection (or presumed infection) act by killing mycobacteria. However, they do 
this by disrupting different elements of the mycobacterial metabolism or structure.56 Selecting 
the best drug or combinations to kill different populations, including metabolically inactive 
organisms, requires careful consideration and evaluation. It is possible that this might permit 
more effective or shorter treatment with less toxicity. 
Dosages of Medications 
Optimizing tuberculosis infection treatment also requires optimization of dosage. Increasing the 
milligram per kilogram dosage may mean greater efficacy, permit intermittent dosing, or allow 
shorter treatment. Isoniazid given at higher doses (e.g. 15-20mg/kg) has been used to treat 
multidrug-resistant organisms (resistant to rifampicin and isoniazid) causing both infection and 
disease.57,58 Comparing efficacy of this dosage with standard (10mg/kg) dosing has not been 
performed for the treatment of tuberculosis infection. Investigators are using increasingly high 
dosages of rifampicin (now up to 50mg/kg) for the treatment of tuberculosis disease in 
adults.59,60 These higher dosages have not been evaluated in the treatment of tuberculosis 
infection.  
  
Additional and Host-Directed Therapies 
It is also important to evaluate host-directed therapies and/or vaccines that do not aim to kill 
mycobacteria directly but assist to eliminate organisms. These might include drugs and/or 
vaccines that modulate parts of the immune system, inhibit efflux pumps or ‘wake’ inactive 
mycobacteria.61 The unique changes across the age-groups of children also need to be included 
in these evaluations as distinct immunological changes during puberty and early adolescence 
may alter these responses.   
Unintended Consequences 
When considering treatment of tuberculosis infection, the concept of ‘first do no harm’ needs to 
extend beyond tolerability and toxicity. Drugs which have broad antibacterial activity and are 
taken for long durations are likely to have other effects. These might be negative, in terms of the 
promotion of drug resistance in non-mycobacterial bacteria,62 or disruption of a ‘healthy’ 
microbiome.63 These unintended effects may also be positive, in terms of reduction in other 
bacterial infections, improved growth, better development and a reduction in life-threatening 
infections. These effects are rarely captured in current treatment trials and any study which 
seeks to evaluate new therapies for tuberculosis infection should evaluate such non-specific 
actions.  
Developing Regimens 
A relatively limited number of regimens are currently recommended to treat drug-susceptible 
tuberculosis infection and no regimen is widely recommended to treat drug-resistant 
tuberculosis infection.52 It is generally accepted that if a regimen is effective in an adult 
population, it will be effective in children.64 However, the formulation is far more important in 
children than adults and the historical crushing of adult tablets should no longer be an 
acceptable solution. The dosing in children required to achieve serum concentrations equivalent 
to effective serum concentrations in adults need to be elucidated, as do child-specific safety 
parameters. In the evaluation of rifapentine, a large initial study was conducted to demonstrate 
efficacy,65 with recruitment of children continuing after the primary trial had closed to make 
sure that enough data were available to document safety in the paediatric population.66 
Knowledge gaps, however, remain in very young children <2 years, who have the highest risk of 
tuberculosis disease progression. Given that children have less concomitant pathology (such as 
existing lung damage that might act as a site difficult to clear of mycobacteria) and are able to 
tolerate higher dosages of most tuberculosis medications, it may be possible to treat children 
with even shorter durations of therapy than adults. To evaluate such regimens, efficacy trials 
would be required. However, creative trial designs are needed as the conventional approach 
  
used to evaluate new tuberculosis infection treatments is to perform a non-inferiority trial 
comparing the new regimen with an established regimen. Given the rarity of disease endpoints 
in the absence of any treatment, and even fewer with established regimens, these trials are 
necessarily large, expensive and of long duration. Duration response trials have been suggested 
as one way that treatments of different durations could be evaluated.67  
 
CONCLUSIONS 
There is a pressing need to better understand the pathophysiology and natural history of 
tuberculosis infection in children from birth to adulthood, to develop tests that better identify 
those at the highest risk of disease progression, to target the delivery of tuberculosis infection 
treatment to those most likely to benefit from it, and to develop and implement treatments that 
are shorter and easier to give. Much can be learnt from studies in adults, but for many questions, 
research needs to be conducted in children specifically. One of the most efficient methods of 
investigating these questions is to embed basic science research into already established clinical 
cohorts and clinical trials and collect relevant specimens during the conduct of such studies.  
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 FIGURE LEGENDS 
Figure 1. The dynamic spectrum from M. tuberculosis exposure to tuberculosis disease in 
children.  
Footnote: It should be noted that for some children severe disease can be caused by a low 
bacillary load that has disseminated widely, such as in miliary tuberculosis or tuberculosis 
meningitis  
Figure 2. Four of many potential responses to tuberculosis infection.  
Footnote: Top left panel: Following exposure, organisms cleared by physical mechanism or by 
the innate immune system without sensitizing the adaptive immune system. This child will be 
TST or IGRA negative. Top right panel: Following exposure, the organisms breech the physical 
and innate defenses with local proliferation. The organism is then contained but not cleared by 
the adaptive immune system with subsequent cycles of proliferation and containment. This 
child with be TST/IGRA positive but does not have tuberculosis disease. Bottom left panel: 
Following exposure, the organisms breech the physical and innate defenses with local 
proliferation. The organism is then contained but not cleared by the adaptive immune system. 
At a future time, the organism proliferates without containment and disease results.  Bottom 
right panel: Following exposure, the organisms breech the physical and innate defenses and 
then proliferate without effective containment by the adaptive immune system. Rapid 
progression to tuberculosis disease follows 
Figure 3. The natural history following exposure to an infectious tuberculosis case.  
Footnote: A child is shown sampled at three time-points following exposure. At all points the 
child is clinically well. However, the stage of tuberculosis infection natural history would be 
unclear, and the immune responses may be very different between the different time-points. 
This is a simplified representation and in a high tuberculosis burden setting this situation could 
be complicated by re-exposure and re-infection. 
Figure 4. A conceptual framework for understanding the relationship between ‘true’ 
tuberculosis infection, a positive test of infection, and a child at risk of future disease 
progression 
  
Table 1 – Research priorities for improved management of paediatric tuberculosis infection  
 Research Need Study Suggestions 
Understanding 
pathophysiology 
Define immuno-phenotypes most likely to progress to tuberculosis disease (in 
particular sub-clinical tuberculosis) in order to identify those children and 
adolescents who would benefit most from tuberculosis infection treatment 
Large household contact studies & large prospective longitudinal analyses 
of immuno-phenotypes*  
Bio-banking of samples from ongoing tuberculosis household contact 
studies in children. 
Investigate if previous tuberculosis infection and containment protects against 
disease development in the face of further exposure and, if so, whether 
treatment of tuberculosis infection might impair this immunity 
Studies in animal models through exposure, infection testing and re-
exposure 
Explore reasons for persistently negative tests of infection (IGRA and TST) 
In children heavily exposed to tuberculosis, compare innate immune 
responses in children with persistently negative IGRA/TST results and 
those with positive test results 
Understand the impact of age on mycobacterial immune responses 
Juvenile animal studies to define ontogeny of mycobacterial immune 
responses 
in vitro human studies exploring ontogeny of mycobacterial immune 
responses 
Understand the role of mucosal immunity in tuberculosis infection following 
exposure to determine role of alternative vaccine routes 
Animal and in vitro human studies of mycobacterial mucosal immunity in 
children of different ages* 
Identification of 
tuberculosis 
infection  
Technical improvement of IGRAs to diagnose tuberculosis infection in young 
children 
Technical research to: 1) Reduce requisite blood volumes; 2) decrease 
incidence of indeterminate results among young children 
Improvement of access to a diagnostic of tuberculosis infection in children 
Technical research to develop a point-of-care diagnostic platform for 
detection of M tuberculosis infection that minimizes blood volume  
Validation in young children of a diagnostic biomarker of sub-clinical disease 
discovered in older children or adults. 
Large prospective observational study of young children for development 
of tuberculosis disease with longitudinal collection of biological 
specimens.* 
Biomarker discovery in young children for diagnostic biomarkers of sub-
clinical tuberculosis 
As for validation studies of diagnostic biomarkers of subclinical 
tuberculosis disease* 
tuberculosis 
infection 
treatment 
Explore the shortest, effective regimen for treatment of drug-susceptible 
tuberculosis infection  
Randomized cluster non inferiority study 
Prevention of infection trials – either with novel vaccines or BCG re-
vaccination 
Duration randomization trials 
Explore the shortest, effective regimen for treatment of drug-resistant 
tuberculosis infection  
Randomized cluster superiority study 
Prevention of infection trials – either with novel vaccines or BCG re-
vaccination 
Duration randomization trials 
  
Obtain pharmacokinetic data on all regimens for all ages of children 
Embed pharmacokinetic studies in all cohorts and trials 
Conduct rifapentine pharmacokinetic studies in children <2 years 
Palatability and acceptability of proposed new formulations or regimens Nested social science evaluations within randomized study  
Explore non-specific effects of current and novel anti-tuberculosis treatment, 
both positive and negative, including impact on the microbiome 
Nested within randomized cluster superiority or non-inferiority study 
 
Explore role of host directed therapies, with a focus on different effects with 
age 
Prevention of infection trials – either with novel vaccines or BCG re-
vaccination 
Trials of host-directed therapies in addition to antimicrobial agents 
Implementation research outcomes evaluation with robust monitoring and 
evaluationt 
Step wedge design within routine implementation settings evaluate cost, 
coverage and sustainability 
 
TST: tuberculin skin test; IGRA: interferon-gamma release assay; BCG: Bacillus Calmette–Guérin 
*These studies would address more than one research need. These studies would ideally be embedded within vaccine trials, diagnostic biomarker studies or household contact studies with a common entry 
point of household exposure 
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